01.22.15
Dynport Vaccine Co. has selected WCCT Global, a full service CRO, as a strategic partner, along with two other CROs, to support clinical trials evaluating anti-infective drugs with the National Institute of Allergy and Infectious Diseases (NIAID).
WCCT Global will support Phase I studies to demonstrate the safety of investigational therapeutic products being studied by the NIAID and will provide data for appropriate human dosing in later phase development. The therapeutic agents include potential medications against bacterial, parasitic, and fungal pathogens.
This partnership is in addition to the recent collaboration for influenza challenge research.
WCCT Global's chief executive officer, Dr. Kenneth Kim said, "WCCT Global was chosen as a strategic partner because of our influenza challenge capabilities and our excellent track record in the successful execution of phase I studies for anti-infective agents. We look forward to working with DynPort and the other partners in this exciting research venture."
WCCT Global will support Phase I studies to demonstrate the safety of investigational therapeutic products being studied by the NIAID and will provide data for appropriate human dosing in later phase development. The therapeutic agents include potential medications against bacterial, parasitic, and fungal pathogens.
This partnership is in addition to the recent collaboration for influenza challenge research.
WCCT Global's chief executive officer, Dr. Kenneth Kim said, "WCCT Global was chosen as a strategic partner because of our influenza challenge capabilities and our excellent track record in the successful execution of phase I studies for anti-infective agents. We look forward to working with DynPort and the other partners in this exciting research venture."